Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

t is being prepared.

?These three Phase II clinical trials sponsored by NCI are components of a clinical trials program designed to identify signals of clinical activity of ispinesib across multiple tumor types,? stated Dr. Andrew A. Wolff, Cytokinetics Senior Vice President of Clinical Research and Development and Chief Medical Officer. ?Although these three trials did not meet the protocol-specified criteria for progression, we are encouraged by the anti-cancer activity of ispinesib observed to date in three other Phase II trials in breast, ovarian and non-small cell lung cancers. Based on these data, we plan to move forward in further clinical development of ispinesib with a focused approach to the potential treatment of breast cancer with ispinesib.?

Clinical Trials of Ispinesib

Ispinesib has been the subject of a broad Phase II clinical trials program under the sponsorship of GlaxoSmithKline (GSK) and is also being developed in collaboration with the NCI. GSK has sponsored three Phase II clinical trials, one evaluating ispinesib as second- or third-line treatment for patients with locally advanced or metastatic breast cancer, one evaluating ispinesib as second-line treatment for patients with non-small cell lung cancer, and one evaluating ispinesib as second-line treatment for patients with advanced ovarian cancer. Enrollment in all of these trials has been closed. To date, clinical activity with ispinesib has been observed in breast cancer, in non-small cell lung cancer, and ovarian cancer with the more robust clinical activity observed in a Phase II clinical trial evaluating ispinesib in the treatment of metastatic breast cancer patients that have failed treatment with taxanes and anthracyclines. In this clinical trial, The best overall responses observed with ispinesib were partial responses in 4 of 45 evaluable patients as measured by the RECIST criteria. Responses were confirmed by independent radiology review and were seen in
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015  The U.S. Food ... (filgrastim-sndz) -- the first biosimilar product approved in ... points toward growth in the contract manufacturing organization ... CMO industry is geared to the production of ... major biopharmaceutical products. The healthcare market research publisher,s ...
(Date:5/22/2015)... May 22, 2015  The Mesothelioma Victims Center ... of mesothelioma get the best possible compensation, and they ... with this rare cancer caused by exposure to ... information related to treatment options such as a ... the Mesothelioma Victims Center anytime at 866-714-6466. ...
(Date:5/22/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... ("EPS"), today announced that its CGuard TM Embolic Prevention ... Prof. Piotr Musialek , at the EuroPCR ... . PARADIGM, an investigator-initiated P rospective ... roti D revascularization I n symptomatic and increased-risk ...
Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... honors Anne King as a 2015-2016 inductee ... She is recognized with this prestigious distinction for leadership ... organization exclusively for professional women, boasting more than 700,000 ... "I’m pleased to welcome Anne into this exceptional group ...
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... honors Lisa Ferrara, Ph.D., as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... organization exclusively for professional women, boasting more than 700,000 ... pleased to welcome Lisa into this exceptional group of ...
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... and distributor of patented products, announces the Hidee-Hose, an ... pants or shorts. , "The Global Women's Hosiery industry ... says Scott J. Cooper, CEO and Creative Director of ... of the hosiery industry is steering ahead and is ...
(Date:5/25/2015)... May 25, 2015 A recent report for ... 1,000 persons have died as a direct result of an ... marks a 33% rise in overdose deaths attributed to prescription ... “This issue doesn’t care about geography. This issue doesn’t care ... doesn’t care about class.” As the state of Mass. reels ...
(Date:5/25/2015)... ProDrop Light Show allows users to now have ... a click of a mouse. Users have full control over angle ... Cut Pro X. , ProDrop Light Show gives users 30 fully ... much more leaving infinite possibilities all within Final Cut Pro X. ... presets, users can apply their very own media files or text ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Anne King, Operating Principal at Keller Williams, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 3Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2
... News) -- Women diagnosed with breast cancer who also suffer ... who just have breast cancer, according to researchers. Even ... chronic illness, those who had conditions such as heart disease, ... rate, the study authors reported in the June 30 online ...
... African-Americans are less likely than whites to receive ... to a hospital soon enough for time-sensitive treatment and ... are eligible for treatment, no racial disparity was found. ... University Medical Center study involving the review of almost ...
... News) -- About two-thirds of Internet sexual offenders bring up ... adolescents and young adults, a new study has found. ... can pose to some young people, according to the researchers ... the American Journal of Nursing . "The use ...
... Today the International and American Associations for Dental Research announced ... ) has increased its Five-Year Scientific Impact Factor (SIF) from ... category, the Journal ranked #1 in Article Influence. This news ... rankings, published by the Journal Citation Reports (JCR). This latest ...
... recognize and encourage cutting-edge research in key areas of ... Medicine (AOSSM) will present nine research awards and two ... Diego, California. As a leader in orthopaedic sports ... initiatives and projects around the country. Highlights of this ...
... will result in the potential exclusion of up to 220,000 ... a new policy brief from the UCLA Center for Health ... percent of all uninsured children in California. ... coverage but may not apply, due to confusion about new ...
Cached Medicine News:Health News:Breast Cancer Plus Other Health Issues Linked to Worse Outcomes 2Health News:Georgetown research identifies key reasons racial disparities exist in emergent stroke treatment 2Health News:Internet Sex Offenders Reveal Some Patterns 2Health News:Journal of Dental Research increases its scientific impact factor 2Health News:AOSSM presents prestigious research awards at annual meeting 2Health News:AOSSM presents prestigious research awards at annual meeting 3Health News:AOSSM presents prestigious research awards at annual meeting 4Health News:Up to 220,000 California children excluded from health care reform due to immigrant status 2
... with Accutrol is similar in design to ... it incorporates a temperature probe at the ... probe can accurately determine the patient's core ... temperature accuracy comparable to a pulmonary artery ...
... These markers are available with 16 or 24 circular ... diameter, and an outer 9.5mm diameter. The markers are ... one single step for a 16 or 24 running ... points on the cornea to achieve a precise and ...
... Ultra Micro Shafts For Insertion Through ... For Light-Weight ... ,Curved Shafts For A More Comfortable Approach., ... ,Protective Cap Supplied For Protection Of Jaws ...
... technology allow the incredible sharpness of diamonds ... cost. Proven diamond blade sharpness improves stromal ... postoperative result. The knives offer unlimited uses, ... widths and configurations. The diamonds are available ...
Medicine Products: